Pfenex Inc. (NASDAQ:PFNX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $18.50 for the company and are predicting that the company will post $0.05 EPS for the current quarter, according to Zacks. Zacks has also given Pfenex an industry rank of 46 out of 255 based on the ratings given to its competitors.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pfenex in a report on Monday, October 28th.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Further Reading: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.